146 related articles for article (PubMed ID: 27188232)
1. Splenic scintigraphy for further differentiation of unclear (68) Ga-DOTATOC-PET/CT findings: Strengths and limitations.
Werner C; Winkens T; Freesmeyer M
J Med Imaging Radiat Oncol; 2016 Jun; 60(3):365-9. PubMed ID: 27188232
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of combined imaging with
Maffey-Steffan J; Uprimny C; Moncayo R; Kroiss AS; Virgolini IJ
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(5):325-327. PubMed ID: 29739708
[No Abstract] [Full Text] [Related]
3. Differentiation of insulinoma from accessory spleen by
Gezer E; Çetinarslan B; Karakaya D; Cantürk Z; Selek A; Sözen M; İşgören S
BMC Endocr Disord; 2021 Jan; 21(1):6. PubMed ID: 33413309
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
5. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
[TBL] [Abstract][Full Text] [Related]
8. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
9. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
[TBL] [Abstract][Full Text] [Related]
10. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
11. Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors: A case report.
Tolomeo A; Lopopolo G; Dimiccoli V; Perioli L; Modoni S; Scilimati A
Medicine (Baltimore); 2020 Feb; 99(7):e19162. PubMed ID: 32049844
[TBL] [Abstract][Full Text] [Related]
12. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
13. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
15. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
[TBL] [Abstract][Full Text] [Related]
16. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors.
Thuillier P; Bourhis D; Metges JP; Le Pennec R; Amrane K; Schick U; Blanc-Beguin F; Hennebicq S; Salaun PY; Kerlan V; Karakatsanis N; Abgral R
Sci Rep; 2021 Mar; 11(1):4727. PubMed ID: 33649421
[TBL] [Abstract][Full Text] [Related]
18. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
20. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.
Miederer M; Seidl S; Buck A; Scheidhauer K; Wester HJ; Schwaiger M; Perren A
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):48-52. PubMed ID: 18807033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
